zhoujing
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer (NCT07018063) | zhoujing | 2025-10-01 |
Track zhoujing automatically
Every clearance here is in the API, with alerts when new ones post.